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 We evaluated the ventricular mechanical effects of 
PhosphodiesteraseIII (PDEIII) inhibitors in the failed heart 
after global ischemia induced by ventricular fibrillation 
(VF) using the left ventricular pressure-volume relationship 
(PVR). In 14 anesthetized open-chest dogs, left ventricular 
PVR was measured using a conductance catheter. Under ad-
ministration of milrinone (MIL, n=7) and olprinone (OLP, 
n=7), the slopes of the LV end-systolic pressure-volume 
(Emax), arterial end-systolic pressure-stroke volume rela-
tions (Ea), ventriculoarterial coupling (Ea/Emax) and preload 
recruitable stroke work (PRSW) were obtained to evaluate 
changes in LV performance. The duration of VF was 1 min 
without cardiopulmonary bypass (CPB). OLP and MIL sig-
nificantly increased the Emax and PRSW values in the failed 
heart after VF, and there was no dose-effect relationship at 
MIL doses of 0.25 to 0.75 µg/kg/min or at OLP doses of 0.1 to 
0.3µg/kg/min. The Ea/Emax value after VF was signifi-
cantly lower in the presence of OLP or MIL than in the ab-
sence of these drugs (-45.3% with OLP and -46.5% with 
MIL). The results indicate that in the heart after transient 
global ischemia, both OLP and MIL improve hemodynamic 
and mechanical states in terms of ventriculoarterial cou-
pling. 
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ship (ESPVR). Several experimental studies have found 
that analyzing ventriculoarterial coupling using the 
time-varying elastance model is useful in evaluating the 
relationship between ventricular contractility and arte-
rial afterload as energetic assessment( `-41, and the method 
has been implemented in several types of study("). 
Phosphodiesterase i1I (PDE III) inhibitor, catecholamines 
and calcium sensitizing agents have been assessed in dis-
eased human hearts". Furthermore, several studies 
have analyzed the influence of ventricular fibrillation 
(VF) on postfibrillatory cardiac function"', 12) , but few 
studies have assessed global ischemia induced by VF 
without cardiopulmonary bypass (CPB), that is the 
novel condition of the present study compared with 
previous studies. The first purpose of this study is to 
evaluate left ventricular hemodynamic and mechanical 
effects of PDE III inhibitors in the failed heart after 
global ischemia induced by VF from the view point of 
ventriculoarterial coupling analyzed with left ventricu-
lar pressure-volume relationship (PVR). The second 
purpose of this study is to compare olprinone (OLP) 
and milrinone (MIL) in terms of hemodynamic and 
mechanical efficacies after the transient global 
ischemia.
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Introduction
 Left ventricular function has recently been assessed by 
the conductance catheter method, which measures the 
left ventricular end systolic pressure-volume relation-
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Materials and Methods
Preparation of animals 
 All experimental procedures and protocols described 
in this study were approved by the Animal Care and 
Use Committee of Nagasaki University School of 
Medicine. Fourteen adult mongrel dogs with a mean 
weight of 11.4 -L 2.9kg were premedicated with a 
subcutaneous injection of ketamine hydrochloride (10 
mg/kg) and anesthetized with intravenous sodium 
pentobarbital (25mg/kg). Small supplemental doses of 
sodium pentobarbital were administered to each dog to 
keep stable hemodynamics and oxygenation, in which 
blood pressure, heart rate (HR), and arterial blood 
gases were monitored. Under anesthesia, dogs were
intubated and ventilated by a mechanical ventilator 
with intermittent positive pressure in the supine posi-
tion. The mean respiratory rate was maintained at 14 
breaths per minute and tidal volume was adjusted to 
20m1/ kg. The arterial pH, Po Z , and Pco 2 were main-
tained within their physiological ranges. A midline 
sternotomy was performed in the supine position and 
the heart was suspended in a pericardial cradle. To 
measure left ventricular pressure a micromanometer-
tipped catheter (Model MPC-500, 5F, Millar Instruments, 
USA) was inserted from the left ventricular apex. A 
conductance catheter (ANP-455, 7F, Leycom, Netherlands) 
was also inserted into the left ventricular apex to 
measure left ventricular volume. These catheters were 
positioned parallel to the long axis of the left ventri-
cle. A drug infusion line was placed at the base of pul-
monary artery, and snaring tape was placed around 
the inferior vena cava (IVC) to change the preload. 
Before starting the experiment, a bolus injection of 
hypertonic saline solution (5% NaCI) into the pulmo-
nary artery was induced to calibrate conductance of 
the surrounding tissues("'. Left ventricular PVR was 
simultaneously obtained by a conductance catheter at-
tached to a stimulator/ processor (Sigma-5, Leycom, 
Netherlands) via the micromanometer-tipped catheter.
Experimental protocol 
 The animals were divided into two groups, one of 
which was given milrinone (MIL; n=7) and the other 
received olprinone (OLP; n = 7) .The administration rate 
of the PDE III inhibitor was regulated appropriately 
based on clinical doses. At first in both groups PVR 
was obtained by transient IVC snaring for 10 seconds 
to reduce preload under the end-expiratory phase with 
no medication. Thereafter, VF was electrically induced 
by a direct current wave of 24v (0.5A). The heart was 
maintained in a state of fibrillation for 1 min, and 
then cardiac beating was restored with a direct cur-
rent shock of 10 Joules. After Imin, PVR was obtained 
by the same procedure. Over the next 30 min, the 
heart was kept beating without medication, after the 
parallel conductance was re-checked a control PVR 
value was measured before drug administration. In the 
MIL group, MIL was first administered at 50,ug/kg for 
10 min as a loading dose. Thereafter, MIL was 
administered at a rate of 0.25 pg/kg/min continuously 
for 20 min and PVR was measured. In the same fash-
ion, PVR values were obtained at dose rates of 0.5 pg 
/kg/min and 0.75 pg/kg/min. Under a continuous infu-
sion of MIL at a rate of 0.75 pg/kg/min, VF was in-
duced using the same method. The heart was kept 
fibrillated for 1 min and restored with direct current
shock. After 1 min, PVR was obtained in the same 
manner. In the OLP group, OLP was first administered 
at 10,ug/kg for 5 min as a loading dose. Thereafter, 
OLP was administered at a rate of 0.1 pg/kg/min for 
20 min and PVR was measured. In the same manner 
PVR values were obtained at rates of 0.2,ug/kg/min 
and 0.3 pg/kg/min. The measurement of PVR after sec-
ond VF was done during a continuous infusion of OLP 
at a rate of 0.3 pg/kg/min as described for the MIL 
group.
Analysis of left ventricular pressure-volume relationship 
  To evaluate changes in LV performance, the slopes 
of the LV end-systolic pressure-volume (Emax), arterial 
end-systolic pressure-stroke volume relationship (Ea), 
ventriculoarterial coupling (Ea / Emax) and preload 
recruitable stroke work (PRSW) were obtained by the 
conductance catheter method. Pressure-volume loops 
were recorded, during 10-second caval snaring as the 
sequence of beats following left ventricular preload re-
duction (Fig.1). The left ventricular PVR during 
preload reduction was fitted using linear regression 
analysis to: 
ESP=Emax (ESV-V0), 
where ESP is the end-systolic pressure, ESV is the 
end-systolic volume, Vo is the volume axis intercept of 
the ESPVR and Emax is the load-independent contrac-
tile index. The value of Ea, which is the slope of end-
systolic pressure-stroke volume relationship represents 
arterial load as an effective arterial chamber related to
Fig. 1. Representative pressure-volume loops obtained by con-
ductance catheter methods during caval snaring and diagram 
showing Emax, Ea and Vo 
Emax; slope of LV end-systolic pressure-volume relationship, 
Vo; the volume intercept of end-systolic pressure-volume rela-
tionship, Ea; negative value of diagonal line connecting end-
systolic pressure-volume point and end-diastolic point on vol-
ume axis.
the Windkessel parameters of the arterial system. 
Thus, 
Ea= ESP/SV, 
where Ea is the negative value of the slope of the di-
agonal line connecting the end-systolic pressure-
volume point and the end-diastolic point on the vol-
ume axis (Fig.1). The ratio Ea / Emax represents 
ventriculoarterial coupling. When effective arterial 
elastance equals ventricular elastance, that is, when 
Ea/Emax=1, stroke work (SW) should be maximized 
because SW is expressed as: 
SW =ESPX SV=EaX (EDV-Vo) 2/(1 +Emax/Ea) 2, 
where EDV is the end-diastolic volume and SV is 
stroke volume. In this manner, energetic effects were 
determined by ventriculoarterial coupling 1 3) . Canine 
experiments have shown that the left ventricle per-
forms maximal external work relative to the arterial 
load when the ventricular and arterial elastance are 
equalized('). As other measure of the LV contractile 
state, PRSW is generally accepted as the load-
insensitive contractile index, namely, the linear rela-
tionship between LV stroke work and end-diastolic 
volume("""".
within each group throughout whole study. Time re-
lated differences in HR, ESP, Emax, Ea, Ea/Emax and 
PRSW in the OLP group were significant. In the MIL 
group, there were no significant differences in HR or 
ESP. Figure 2 shows dose-effect relations in the HR of 
the two groups. In each group, there were no signifi-
cant differences between several experimental states. 
In addition, at the same state there was no significant 
difference between MIL and OLP groups. Figure 3 
shows dose-effect relations in the ESP of the two 
groups. After beating was restored from the initial 
fibrillated state ESP tended to decrease with admini-
stration of PDE Ill inhibitors, but there were no signifi-
cant differences between several experimental states in 
each groups. Figure 4 shows dose-effect relations in 
the Emax values of the two groups. At VF30 state, Emax 
did not significantly differ from the baseline state in 
both groups. After starting the administration of PDE 
III inhibitors, Emax values maximally increased to 17.4
HR
Statistics 
 End-systolic PVR was obtained using linear regres-
sion analysis. All data are reported as means ± standa 
rd deviation (SD). Repeated measures ANOVA com-
pared Emax, Ea, Ea/Emax, RRSW, HR and ESP. When re-
peated measures ANOVA revealed significant differ-
ences according to the F test, matched pairs before 
and after administration of MIL or OLP were com-
pared by a two-tailed paired t test. To compare the 
mean of variables in the MIL group and OLP group, a 
two-tailed unpaired t test was applied. A p value of 
<0.05 was taken to indicate a significant difference.
Fig. 2. Changes of HR in the OLP and MIL groups 
Baseline; control state before VF with no medication, VF30; 
restored beating state after 30min from VF with no medica-
tion, Low; state just after administration at a rate of low dose 
for 20min (OLP;0.1,g/kg/min, MIL;0.25pg/kg/min), Med.; 
state just after administration at a rate of medium dose for 
20min (OLP;0.2 pg/kg/min, MIL;0.50 pg/kg/min), High; state 
just after administration at a rate of high dose for 20min 
(OLP;0.3,ug/kg/min, MIL;0.75sg/kg/min). 
In each group, there was no significant difference at the 
point of dose-effect relation.
Results
SBP
Baseline hemodynamics and conditions 
 Body weight (BW), HR, end-systolic pressure (ESP), 
Emax, Ea, Ea/Emax, PRSW, and Vo did not significantly 
differ between the OLP and MIL groups without medi-
cation before inducing VF as experimental control con-
ditions.
Dose-effect relations in the presence of OLP and MIL 
 In the MIL and OLP groups, repeated measures 
ANOVA detected time-related significant changes
Fig. 3. Changes of ESP in the OLP and MIL groups 
Experimental states were as described in Figure 2. In each 
group, there was no significant difference at the point of 
dose-effect relation.
Emax Ea/Emax
Fig. 4. Changes of Emax in the OLP and MIL groups 
Experimental states were as described in Figure 2. In each 
group, there were significant differences between administrat-
ing states and VF30 state at the point of dose-effect relation.
Ea
Fig. 6. Changes of Ea/Emax in the OLP and MIL groups 
Experimental states were as described in Figure 2. In each 
group, there were significant differences between administrat-
ing states and VF30 state at the point of dose-effect relation.
PRS W
Fig. 5. Changes of Ea in the OLP and MIL groups 
Experimental states were as described in Figure 2. In each 
group, there was no significant difference at the point of 
dose-effect relation.
Fig. 7. Changes of PRSW in the OLP and MIL groups 
Experimental states were as described in Figure 2. In each 
group, there were significant differences between administrat-
ing states and VF30 state at the point of dose-effect relation.
± 3.71 mmHg/ml in the OLP group, and to 16.6 ± 3.16 
mmHg/ml in the MIL group. These changes were sig-
nificant compared to VF30 state at each administrat-
ing states. Figure 5 shows dose-effect relations in the 
Ea value of the two groups. The administration of OLP 
and MIL resulted in similar decreases in both groups, 
but there were no significant differences between sev-
eral experimental states in each groups. Figure 6 shows 
dose-effect relations in the values of ventriculoarterial 
coupling (Ea/Emax) of the two groups. There were no 
significant differences between baseline state and 
VF30 state in both groups (+10.4%, p=0.25 in the 
OLP group and +23.7%, p=0.27 in the MIL group). 
When a stable contractile state was attained after 
beating was restored from the initial fibrillated state 
with no medication, Ea /Emax maximally increased in 
both groups. However the values of Ea/Emax decreased 
to 0.69±0.29 in the OLP group (-72.1%), and 0.73±0. 
33 in the MIL group (-66%) under the continuous ad-
ministration of OLP or MIL, respectively. Compared to 
VF30 state, there were significant differences between 
several experimental states in each groups. In addition 
during the entire experimental course Ea/Emax did not
statistically differ between the OLP and MIL groups. 
Figure 7 shows dose-effect relations in the PRSW 
value of the two groups. The administration of OLP or 
MIL resulted in similar changes in PRSW compared 
with those of Emax. There were significant differences 
between administrating states and VF30 states in each 
groups. Effects of OLP and MIL on hemodynamics in 
VF-induced failed hearts were summarized in Table 1 
and 2. At restored beating state from the VF with con-
tinuous high dose administration of OLP, the value of 
Ea/Emax was significantly lower compared to restored 
beating state from the VF with no drug (-45.3%, 
p=0.028). In MIL group, Emax was higher and the 
value of Ea/Emax was lower (-46.5%, p=0.01) signifi-
cantly compared to restored beating state from the VF 
with no drug. As compared with OLP group, the value 
of Emax of MIL group was significantly higher in the 
restored beating state from the VF with continuous 
high dose administration. In other values, there was no 
significant difference between two groups.
Table 1. Effects of OLP on the hemodynamics after VF 
Baseline; control state before VF with no medication, No 
drug after VF; restored beating state after Imin from VF 
with no medication; OLP after VF; restored beating state 
after lmin from second VF under continuous administration 
at a rate of 0.3,ug/kg/min.
                  Baseline After VF 
                           No drug OLP 
HR (bpm) 140±21.5 139±22.6 128±19.7 
ESP(mmHg) 116±24.8 128±21.2 113±10.2 
Emax (mmHg/ml) 7.46±2.04 5.53±2.94 6.70±0.95 § 
Ea (mmHg/ml) 11.7±3.10 11.8±3.94 8.91±1.88 
EalEmax 1.74±0.80 2.47±0.80 1.36±0.36 
PRSW (103dyn.cm-2) 69.8±24.1 51.9±14.9 86.8±47.6
P<0.05 vs no drug 
P<0.05 vs MIL(Table 2)
Table 2. Effects of MIL on the hemodynamics after VF 
Baseline; control state before VF with no medication, No 
drug after VF; restored beating state after lmin from VF 
with no medication; MIL after VF; restored beating state 
after lmin from second VF under continuous administration 
at a rate of 0.75,ug/kg/min.
                  Baseline After VF 
                           No drug MIL
HR (bpm) 128±34.8 124±21.2 132±13.3 
ESP(mmHg) 117±12.9 112±15.1 110±17.0 
Emax (mmHg/ml) 8.85±2.54 6.23±1.76 9.76±2.31 § 
Ea (mmHg/ml) 15.0±5.70 13.0±4.79 10.7±3.67 
Ea/Emax 1.73±0.71 2.15±0.71 1.15±0.53 
PRSW (103dyn.cm-2) 55.9±16.3 50.9±19.2 71.9±30.7
Discussion
P<0.05 vs no drug 
P<0.05 vs OLP (Table 1)
 Congestive heart failure has recently been clinically 
treated with PDE III inhibitors"'), which confer the 
benefits of augmented cardiac output and reduced ven-
tricular filling pressure. The PDE III inhibitors have 
positive inotropic effects on the heart and vasodilating 
activities. The effect of PDE f inhibitor is mediated by 
the inhibition of selective PDE 111 isoenzymes with an 
increase in cyclic adenosine monophosphate. Cytosolic 
free Ca is thought to be increased via a cascade of re-
actions in the heart resulting in increased contractility. 
On the other hand, cytosolic free Ca of vascular 
smooth muscle cells is thought to be decreased result-
ing in vasodilatation, which manifests as a signifi-
cantly increased distensibility of the carotid arteries 
after the administration of PDEM inhibitor("). 
 The effectiveness of PDE III inhibitor on ventriculoarterial 
coupling and myocardial energetics has been shown in 
the diseased human heart'°). In that study PDE III
inhibitor improved ventriculoarterial coupling more 
than dobutamine, with a resultant increase in mechani-
cal efficiency. Another study showed that Emax in-
creased to the same extent with dobutamine, PDE III 
inhibitor and Ca sensitizing agent and that Ea was un-
changed with dobutamine or Ca sensitizing agent, but 
decreased with PDE 1U inhibitor. Thus Ea/Emax was de-
creased by all inotropic agents but to the greatest ex-
tent by PDE III inhibitor"). In this ventriculoarterial 
coupling, the arterial system is treated as if the elastic 
chamber has volume elastance Ea just as the left ventri-
cle is treated as an elastic chamber with end-systolic 
elastance Emax(1). In this sense, ventriculoarterial cou-
pling represents the function of both the ventricle and 
the arterial system, so it is reasonable to evaluate PD 
E III inhibitor which affects both the ventricle and the 
arterial system from the viewpoint of ventriculoarterial 
coupling. 
 Several studies have analyzed human hearts with local 
ischemia due to myocardial infarction","). Furthermore, 
several studies have assessed whole ischemic hearts in-
duced by VF under CPB. One such study showed that 
VF for 20 to 40 min does not depress postfibrillatory 
contractility when normal coronary blood perfusion is 
maintained in the canine left ventricle"'). Another 
study showed that a short duration of spontaneous VF 
during CPB might induce subendocardial ischemic dam-
age at lower perfusion pressures (30 and 60mmHg). 
On the other hand, the empty beating heart does not 
induce subendocardial underperfusion at such low per-
fusion pressures'12> 
 We induced ventricular global ischemia in the present 
study using VF without CPB to evaluate left ventricu-
lar mechanical effects in terms of ventriculoarterial 
coupling. It was easy and steady method to get the 
trancient global ischemic state by inducing VF for 
lmin without CPB, so post VF period was chosen as 
the experimental setting. Furthermore these situations 
are not demonstrated in clinical settings but proofed 
under local ischemia in clinical cases as myocardial 
infarction","). As experimental studies there were few 
studies under global ischemia, it was important to meas-
ure Ea/Emax to clear the effect of PDE III inhibitors under 
these settings. The results of this study indicate that 
PDE III inhibitors improve hemodynamic and mechani-
cal effects in the heart after VF-induced brief global 
ischemia without CPB. At the point of postfibrillatory 
left ventricular load-independent contractility, OLP or 
MIL similarly increased the values of Emax and PRSW. 
Yet another study indicated that PRSW may be a 
more linear and reliable index with which to evaluate 
contractility in man"'), but the present study found no 
significant differences between the values of Emax and
PRSW. In this study OLP and MIL similarly increased 
the Em,, and PRSW values in a dose-independent man-
ner. The Ea values tended to decrease with no signifi-
cance, and the values of Ea/ Emax significantly de-
creased in the VF-induced failed hearts. 
 In conclusion, PDE III inhibitors improve hemodynamic 
and mechanical states in the heart after transient global 
ischemia induced by VF in terms of ventriculoarterial 
coupling.
Acknowledgments
I thank Mr. H. Yamashita for invaluable assistance.
References
(1) Sunagawa K, Maughan WL, Burkhoff D, et all: Left ventricular 
    interaction with arterial load studied in isolated canine ventricle. 
    Am J Physiol 245: H773-H780, 1983 
(2) Sunagawa K, Maughan WL, Sagawa K: Optimal arterial resis-
    tance for the maximal stroke work studied in isolated canine left 
    ventricle. Circ Res 56:586-95,1985 
(3) Sunagawa K, Maughan WL, Sagawa K: Stroke volume effect of 
    changing arterial input impedance over selected frequency 
    ranges. Am J Physiol 248:H477-84, 1985 
(4) Burkhoff D, Sagawa K: Ventricular efficiency predicted by an 
    analytical model. Am J Physiol 250:H1021-7, 1986 
(5) Kawaguchi 0, Pae WE, Daily BB, et all: Ventriculoarterial cou-
    pling with intra-aortic balloon pump in acute ischemic heart fail-
    ure. J Thorac Cardiovasc Surg 117: 164-71, 1999
(6) Kolh P, Orio VD, Lambermont B, et all: Increased aortic compli-
     ance maintains left ventricular performance at lower energetic 
    cost. Eur J Cardio-thorac Surg 17:272-278, 2000 
(7) Mori M, Takeuchi M, Takaoka H, et all: Oxygen-saving effect of 
     a new cardiotonic agent, MCI-154, in diseased human hearts. J
    Am Coll Cardiol 29: 613-22, 1997 
(8) Takeuchi M, Takaoka H, Hata K, et all: Effect of inotropic agents 
    on mechanoenergetics in human diseased heart. Cardiac 
     energetics. In Le Winter M., Suga H., (eds) Emax to pressure-
     volume area. Kluwer Academic Publishers, Boston, 201-212, 1995 
(9) Mori M, Takeuchi M, Takaoka H, et all: Lusitropic effects of a 
     Ca" sensitization with a new agent, MCI-154, on diseased 
    human hearts. Cardiovasc Res 73:915-22, 1995 
(10) Takaoka H, Takeuchi M, Odake M, et all: Comparison of the 
    Effects on Arterial-Ventricular Coupling Between Phosphodiesterase
    Inhibitor and Dobutamine in the Diseased Human Heart. J Am 
    Coll Cardiol 22:598-606, 1993 
(11) Yaku H, Goto Y, Futaki S, et all: Ventricular fibrillation does not 
    depress postfibrillatory contractility in blood-perfused dog hearts. 
    J Thorac Cardiovasc Surg103: 514-520, 1992 
(12) Kawaguchi Y, Tominaga R, Yoshitoshi M, et all : Relationship be-
    tween perfusion pressure and myocardial microcirculation in the 
    beating empty or. spontaneously fibrillating heart. Jpn j Surg 15: 
    379-386, 1985 
(13) Baan J, Van der Velde ET, De Bruin HG, et all : Continuous meas-
     urement of left ventricular volume in animals and humans by 
    conductance catheter. Circulation 70: 812-823, 1984 
(14) Glower DD, Spratt JA, Snow ND, et all: Linearity of the frank-
    Starling relationship in the intact heart: the concept of preload 
    recruitable stroke work. Circulation 71:944-1009, 1985 
(15) Takeuchi M, Odake M, Takaoka H, et all: Comparison between 
     preload recruitable stroke work and the end-systolic pressure-
    volume relationship in man. Eur Heart J 13:80-84, 1992 
(16) Konstam MA, Cody RJ : Short-term use of intravenous Milrinone 
    for heart failure. Am J Cardiol 75; 822-826, 1995 
(17) Seki M, Mizushige K, Ueda T, et all: Effect of olprinone, a phos 
    phodiesteraselff inhibitor, on arterial wall distensibility: differen-
     tiation between aorta and common carotid artery. Heart Vessels 
    14: 224-231, 1999
